Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.

Acta haematologica - 1 Jan 2021

Zhou Selena, Tremblay Douglas, Hoffman Ronald, Kremyanskaya Marina, Najfeld Vesna, Li Lihua, Moshier Erin, Mascarenhas John

Abstract excerpt

Treatment options are limited for patients with advanced forms of myeloproliferative neoplasms (MPN) including blast-phase disease (MPN-BP). Decitabine has frequently been deployed but its efficacy and safety profile are not well described in this population. We retrospectively reviewed 42 patients treated with decitabine either alone or in combination with ruxolitinib at our institution: 16 with MPN-BP, 14 with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Decitabine

Share to Kaplan-Meier Estimate

Share to Myeloproliferative Disorders

Share to Neoplasm Staging

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 32160610
DOI: 10.1159/000506146
PMCID: PMC7773003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.PMID 32160610Read ↗

Accelerated and blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Accelerated Phase of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.Semantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?Semantic proximity Read ↗

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM studySemantic proximity Read ↗

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomesSemantic proximity Read ↗

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.Semantic proximity Read ↗

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.